LONDON--(BUSINESS WIRE)--Technavio has announced the top seven leading vendors in their recent global biosimilars market report until 2020. This research report also lists 48 other prominent vendors that are expected to impact the market during the forecast period.
Highlights:
Lengthy development and manufacturing activities and continuous clinical and risk-monitoring studies even after regulatory approval will require high investment cost and reduce the profitability of vendors. These barriers will act as major hindrances to vendors, especially small and emerging vendors with limited investments. Also, vendors have to deal with the growing cost constraints regarding R&D and an increasingly competitive market.
Competitive scenario
According to the report, the global biosimilars market consists of key vendors such as Sandoz, Hospira, Teva Pharmaceuticals, STADA, Celltrion, and Biocon. Sandoz dominated the market, with a share of 52.23% in 2015, followed by Hospira with 17%, Teva Pharmaceuticals with 16%, STADA with 6%, and other with 8.77%.
The dominant position of Sandoz is attributed to its biosimilar offerings such as Omnitrope, Binocrit, and Zarzio. The company pursues organic growth strategies by investing in R&D to develop new biosimilars. It has a strong pipeline of biosimilars in various stages of development, including adalimumab, etanercept, rituximab, epoetin-alfa, pegfilgrastim, and infliximab. Such a strong pipeline allows it to complement its existing biosimilars, thereby enabling it to generate substantial revenue in the future.
“Hospira has a strong presence in high potential indications such as anemia and immune-mediated inflammatory diseases. Hospira capitalizes on a strong operational and financial base of its parent company, Pfizer, to facilitate its activities to develop and launch new biosimilars,” says Barath Palada, one of the lead cardiovascular and metabolic disorders research analysts from Technavio.
Request sample report: http://goo.gl/wr9G8q
Top seven biosimilars market vendors
Sandoz
Sandoz was founded in 1886 and is headquartered in Holzkirchen, Germany. The company provides generics spanning oral solids, gels and patches, injectables, and biosimilars. It operates as the generic pharmaceuticals division of Novartis.
Sandoz has established a presence in the global biosimilars market. It reported revenue of USD 772 million from its biosimilar products, indicating an increase of 25% over that in previous fiscal year. Omnitrope is a recombinant human growth hormone indicated to treat growth failure due to growth hormone deficiency, Turner syndrome, Prader-Willi Syndrome, small for gestational age, and idiopathic short stay treatment of children with growth failure. The product is also indicated for the treatment of individuals with adult onset or childhood onset growth hormone deficiency. Omnitrope received the US FDA's approval in 1987.
Hospira
Hospira was established in 2003 and is headquartered in Lake Forest, Illinois, US. It manufactures generic injectable pharmaceuticals and infusion technologies. As of September 2015, the company operates as a subsidiary of Pfizer.
Retacrit (epoetin zeta) is used to treat anemia in individuals receiving chemotherapy and to reduce the necessity for blood transfusions. It is also used to treat anemia in people with chronic renal failure or other kidney problems; to increase the quantity of blood so people with moderate anemia can self-donate before surgery; and to reduce the necessity for blood transfusions in people with moderate anemia who are about to undergo a major bone surgery.
Teva Pharmaceuticals
Teva Pharmaceuticals was incorporated in 1944 and is headquartered in Petach Tikva, Israel. The company provides generic medicines and specialty pharmaceutical products. Its products are sold in over 100 countries worldwide and has operations in 60 countries. In FY2015, Teva Pharmaceuticals reported revenue of USD 19.7 billion, as compared to USD 20.3 billion in 2014.
Tevagrastim is a short-acting G-CSF, the first of its kind to be approved by the EU. The drug received EC-approval in September 2008. It is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in individuals treated with established cytotoxic chemotherapy for malignancy. It is also used to reduce the duration of neutropenia in individuals undergoing myeloablative therapy after bone marrow transplantation. Tevagrastim is also marketed as Biograstim and Ratiograstim in the EU.
STADA
STADA was founded in 1895 and is headquartered in Bad Vilbel, Germany. Some of its products include Grippostad, Ladival, Covonia, and Aqualor. In FY2014, the company reported revenue of USD 2.74 billion.
Silapo stumulates the bone marrow to produce more red blood cells, and is indicated for the treatment of symptomatic anemia associated with chronic renal failure. In 2007, the company received EC approval for the drug for the treatment of anemia linked with chronic renal failure and chemotherapy.
Biocon
Biocon was founded in 1978 and is headquartered in Bangalore, India. The company manufactures and markets drugs to treat diseases, including diabetes, cancer, and autoimmune diseases. In FY2015, Biocon reported revenue of USD 546.15 billion and spent USD 40.74 million on R&D.
Trastuzumab is a biosimilar of CANMAb, indicated for the treatment of HER-2 positive metastatic breast cancer. In India, trastuzumab was launched in 2014. The launch has enhanced patient access to drug by nearly 30% in India. The product interferes with the growth and spread of cancer cells in the body. The patient recruitment for this product is in progress across over 100 sites in various countries for global Phase III trials.
Celltrion
Celltrion was founded in 2002 and is headquartered in Yeonsu-gu, Incheon, South Korea. The company researches, develops, manufactures, and sells biopharmaceutical products in South Korea and internationally. In FY2014, Celltrion reported revenue of USD 423.94 million and spent USD 62.67 million on R&D.
Herzuma is a biosimilar of Roche’s breast cancer drug Herceptin (trastuzumab). The drug is indicated for the treatment of early and advanced (metastatic) HER2+ breast cancer and advanced (metastatic) stomach cancer. It activates the body’s immune system and suppresses HER2 signals to target and destroy tumors. In January 2014, Celltrion received approval for Herzuma with the Korean Ministry of Food and Drug Safety. In April 2014, the company commenced Phase III clinical trial for its trastuzumab candidate (CT-P6) in individuals with HER2+ breast cancer.
Dr. Reddy's
Dr. Reddy's was founded in 1984 and is headquartered in Hyderabad, Telangana, India. It is an integrated pharmaceutical company with three segments, global generics, pharmaceutical services and active ingredients, and proprietary products. In FY2014 (fiscal year ended March 31, 2015), the company reported revenue of USD 2.38 billion and spent USD 284.41 million on R&D.
Cresp (Darbepoetin alfa) is indicated for the treatment of anemia in individuals with chronic kidney failure or certain cancer types. Darbepoetin alfa is similar to the natural protein human erythropoietin, and acts by stimulating the bone marrow to generate more red blood cells. In August 2010, the company launched Cresp, which is available in vials and pre-filled syringes.
Browse Related Reports:
- Global Generic Drugs Market 2016-2020
- Global Solid Tumors Drugs Market 2016-2020
- Global Analgesics Market 2016-2020
Do you need a report on a market in a specific geographical cluster or country but can’t find what you’re looking for? Don’t worry, Technavio also takes client requests. Please contact enquiry@technavio.com with your requirements and our analysts will be happy to create a customized report just for you.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
